Ref ID: 19220
Author:
J.F. Meis*, D.W. Denning, P.E. Verweij
Author address:
Nijmegen, NL; Manchester, GB
Full conference title:
23rd European Congress of Clinical Microbiology and
Infectious Diseases
Date: 27 April 2014
Abstract:
Objective: The healthcare system in the Netherlands is advanced, but the number of fungal infections (FIs) nationally is not known. Using different populations at risk we have estimated numbers of serious FIs.
Methods: Published papers reporting FI rates from the Netherlands and population data were extracted from www.cbs.nl, www.hiv-monitoring.nl, www.nationaalkompas.nl, www.ncsf.nl, www.cijfersoverkanker.nl, www.transplantatiestichting.nl, www.peritonitis.nl, www.nivel.nl.
Results: Amongst a population of 16.766M, 17.3% are children (0-14 years) and 21% of population are >60 years old. Recurrent vaginal thrush (4+ times annually) affects 5% of women under 50, an estimated total of 219,588.
Of the 1073 cases of pulmonary TB in 2011, 96% HIV negative, 45 new cases of chronic pulmonary aspergillosis (CPA) cases are estimated, a 5-year period prevalence of 142 CPA cases, 25% of all cases (assuming 15% annual mortality). Asthma prevalence in adults is 7.2% (997,378 cases) although 2003 figures suggest 519,800. Assuming that 2.5% of the lower number have ABPA, 13,085 patients with ABPA are likely and 17,153 have severe asthma with fungal sensitisation (SAFS). Of the 16,555 estimated HIV positive patients, only 812 presented with AIDS in 2011 and none developed Pneumocystis pneumonia or cryptococcal meningitis. Estimating the annual incidence of Pneumocystis pneumonia or oesophageal candidosis in other patient groups was not possible. The rate of candidemia was estimated at 5/100,000 population consistent with 838 cases. Candida peritonitis is estimated at 50% of the ICU candidaemia rate, itself estimated to be 70% of all candidaemia. Among haematological/transplant and COPD patients, invasive aspergillosis is estimated at 336 and 240 respectively.
Conclusion: Most serious fungal infections in the Netherlands occur in immunocompromised and respiratory patients. Both community and hospital-based surveillance studies are urgently required to validate or modify these estimates.
Abstract Number: P1040
Conference Year: 2013
Link to conference website: http://registration.akm.ch/einsicht.php?XNABSTRACT_ID=165638&XNSPRACHE_ID=2&XNKONGRESS_ID=180&XNMASK
New link: NULL
Conference abstracts, posters & presentations
-
Title
Author
Year
Number
Poster
-
v
Teclegiorgis Gebremariam [MS]1, Yiyou Gu [PhD]1, Sondus Alkhazraji [PhD]1, Jousha Quran1, Laura K. Najvar [BS]2, Nathan P. Wiederhold [PharmD]2, Thomas F. Patterson [MD]2, Scott G. Filler [MD]1,3, David A. Angulo (MD)4, Ashraf S. Ibrahim [PhD]1,3*,
2024
91
n/a
-
v
Ruta Petraitiene (US)
2024
90
n/a
-
v
Fabio Palmieri (CH), Junier Pilar
2024
89
n/a
-
v
Evelyne Côté (CA)
2024
88
n/a
-
v
Eliane Vanhoffelen (BE)
2024
87
n/a
-
v
Teclegiorgis Gebremariam, Yiyou Gu, Eman Youssef, Sondus Alkhazraji, Joshua Quran, Nathan P. Wiederhold, Ashraf S. Ibrahim
2024
86
n/a
-
v
Thomas Orasch (DE)
2024
85
n/a
-
v
Julien Alex, Katherine González, Gauri Gangapurwala, Antje Vollrath, Zoltán Cseresnyés, Christine Weber, Justyna A. Czaplewska, Stephanie Hoeppener, Carl-Magnus Svensson, Thomas Orasch, Thorsten Heinekamp, Carlos Guerrero-Sánchez, Marc Thilo Figge, Ulrich S. Schubert, Axel A. Brakhage
2024
84
n/a
-
v
Vasireddy Teja, Bibhuti Saha Hod, Soumendranath Haldar (IN)
2024
83
n/a
-
v
Vasireddy Teja, Bibhuti Saha Hod, Soumendranath Haldar (IN)
2024
82
n/a